Abstract
Lung cancer is the leading cause of cancer death in males and the second leading cause of death in females worldwide. Non-small-cell lung cancer (NSCLC) is the main pathological type of lung cancer, and most newly diagnosed NSCLC patients cannot undergo surgery because the disease is already locally advanced or metastatic. Despite chemoradiotherapy and targeted therapy improving clinical outcomes, overall survival remains poor. Immune checkpoint blockade, especially blockade of programmed death-1 (PD-1) receptor and its ligand PD-L1, achieved robust responses and improved survival for patients with locally advanced/metastatic NSCLC in preclinical and clinical studies. However, with regard to PD-1/PD-L1 checkpoint blockade as monotherapy or in combination with other antitumor therapies, such as chemotherapy, radiotherapy (including conventional irradiation and stereotactic body radiotherapy), and target therapy, there are still many unknowns in treating patients with NSCLC. Despite this limited understanding, checkpoint blockade as a novel therapeutic approach may change the treatment paradigm of NSCLC in the future. Here we review the main results from completed and ongoing studies to investigate the feasibility of PD-1/PD-L1 i...Continue Reading
Citations
Aug 27, 2016·Expert Opinion on Biological Therapy·Zvia AgurOfer Shlagman
Nov 15, 2016·Expert Review of Anticancer Therapy·Gautam Kishore ValechaJean Paul Atallah
Dec 21, 2016·Cancer Biotherapy & Radiopharmaceuticals·Zheng DongZhiguang Geng
Jan 26, 2017·Acta Pharmaceutica Sinica. B·Minting LinJianye Zhang
Nov 3, 2017·Medicine·Xiaoying SunBin Li
Jun 21, 2017·International Journal of Molecular Sciences·Ying-Ying LiNiramol Savaraj
Nov 8, 2017·Cell Cycle·Prerna MalaneyVrushank Davé
Dec 7, 2018·PloS One·Kuo-Hao HoKu-Chung Chen
Mar 8, 2018·BMC Cancer·Guannan WangQun Wang
Aug 25, 2017·Cell Death & Disease·Elisabetta CavalcantiMaria Lucia Caruso
Mar 31, 2017·Molecular Pharmacology·Tong WuLiwu Fu
Jul 31, 2019·Expert Opinion on Investigational Drugs·Alvaro H Ingles GarcesJames Larkin
Jun 19, 2017·Targeted Oncology·Olivier BylickiChristos Chouaid
Aug 5, 2017·Journal of Hematology & Oncology·Junyu LongHaitao Zhao
Jul 26, 2019·The Clinical Respiratory Journal·Yuika SasataniHiroaki Satoh
Sep 7, 2017·Current Opinion in Oncology·Leora Boussi, Ruben Niesvizky
Apr 8, 2016·Current Opinion in Pediatrics·Lesley Doughty
Oct 15, 2019·Frontiers in Pharmacology·Siyao DengShun Lu
Jun 11, 2020·Radiation Oncology·Julian TaugnerFarkhad Manapov
Jul 1, 2020·Medicinal Research Reviews·Surya K TripathiBijesh K Biswal
Oct 6, 2018·Oncoimmunology·Sang-Soo KimEsther H Chang
Aug 27, 2016·Clinical and Experimental Pharmacology & Physiology·Junzhong RuanZitong Wang
Jan 1, 2019·Mediators of Inflammation·Monika WalankiewiczJacek Rolinski
Jun 27, 2019·International Journal of Cancer. Journal International Du Cancer·Sang-Soo KimEsther H Chang
Aug 4, 2016·Current Oncology Reports·Raffaele CalifanoAntonio Rossi
May 31, 2020·Mycoses·Samuel OkurutDavid B Meya
Aug 30, 2019·Experimental Hematology & Oncology·Zhenbin QiuWenzhao Zhong
Jan 18, 2021·FEBS Open Bio·Hongxin ZhangJianhui Cai
Dec 29, 2020·Radiation Research·Guanghui CuiSong Zhao
Feb 1, 2022·Journal of Managed Care & Specialty Pharmacy·Sachin Kamal-BahlRichard Willke